Previous 10 | Next 10 |
Study published in Future Oncology Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of a clinical use study demonstrating that manageme...
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that management will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference, December 1-3, 202...
Two Companion Articles Recently Published in SKIN: The Journal of Cutaneous Medicine Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication o...
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of data on two of its skin cancer gene expression profile tests during the 57 th Meeting of T...
The following slide deck was published by Castle Biosciences, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Castle Biosciences, Inc. 2020 Q3 - Results - Earnings Call Presentation
Castle Biosciences, Inc. (CSTL) Q3 2020 Earnings Conference Call November 9, 2020 16:30 ET Company Participants Frank Stokes - Chief Financial Officer Derek Maetzold - Founder, President & Chief Executive Officer Conference Call Participants Max Masucci - Canaccord Genuity Sung Ji Nam - B...
Castle Biosciences (CSTL): Q3 GAAP EPS of -$0.23 misses by $0.11.Revenue of $15.2M (+2.9% Y/Y) beats by $0.2M.Press Release For further details see: Castle Biosciences EPS misses by $0.11, beats on revenue
Q3 2020 revenues of $15.2 million, Q3 2020 YTD revenues of $45.4 million DecisionDx-Melanoma report volume returned to quarterly year-over-year increase Q3 2020 gross margin of 84% Recently received final expanded positive Medicare coverage for DecisionDx-Melan...
Diagnostic gene expression profile test for suspicious pigmented lesions now commercially available in the U.S. Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today ...
Presentations to highlight two of Castle’s skin cancer gene expression profile tests Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that the c...
News, Short Squeeze, Breakout and More Instantly...
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NASDAQ Market:
Castle Biosciences Inc. Website:
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 44 th Annual Growth Conference on Tuesday, Aug. 13, 2024, at ...
Campaign will focus on empowering patients impacted by melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...